Biotech · Public company · Boston, MA, US

Monte Rosa Therapeutics, Inc.

Ticker GLUE · SEC CIK 0001826457

Track this companyFree. Adds Monte Rosa Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials43 recruiting or active

Pipeline programs5From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline5

ApalutamidePhase 2 · Castration-Resistant Prostate Cancer (CRPC)ClinicalTrials.gov · fetched Nov 12, 2026
Oral MRT-2359Phase 2 · Castration-Resistant Prostate Cancer (CRPC)ClinicalTrials.gov · fetched Nov 12, 2026
Oral MRT-2359Phase 2 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
MRT-6160Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
MRT-8102Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026

Study of Oral MRT-2359 With Apalutamide in Prostate CancerPHASE2 · RECRUITING · started Aug 18, 2026ClinicalTrials.gov NCT07745361 · fetched Nov 12, 2026
A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRPPHASE1 · ACTIVE_NOT_RECRUITING · started Jun 27, 2025ClinicalTrials.gov NCT07119125 · fetched Nov 12, 2026
First-in-human Study of MRT-6160 in Healthy SubjectsPHASE1 · COMPLETED · started Aug 7, 2024ClinicalTrials.gov NCT06597799 · fetched Nov 12, 2026
Study of Oral MRT-2359 in Selected Cancer PatientsPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Oct 12, 2022ClinicalTrials.gov NCT05546268 · fetched Nov 12, 2026